About XenTech

XenTech is dedicated to accelerating the development of new anti-cancer therapies by providing with the most relevant science driven preclinical services to our clients and partners.

XenTech is pioneer as developer and CRO for the Patient-Derived primary tumor Xenograft models (PDX) approach.
Our expertise and technology are based on one of the world’s reference and most published collection of PDX.
Our ambition is to foster therapeutic development in Oncology by offering an innovative translational platform, developing clinically relevant tumor models and addressing tomorrow’s needs in preclinical oncology research.

01Our company

XenTech is a spin-off of Institut Curie, France’s largest cancer research institute, where our scientists have published reference articles since 1989, providing the world’s first proof of concept for the development and use of PDXs. 

With over 2000 studies with industrial and academic partners XenTech’s staff has a comprehensive knowledge of PDX based experimental pharmacology.

Our team ensures high quality research and ethical standards and is continuously working to keep up to date with new technologies

01Our team

XenTech’s staff is composed of highly trained and dynamic researchers, engineers and technicians with a solid experience in experimental pharmacology, tumor xenograft models, as well as molecular and cell biology. The whole team works together to keep up with scientific and technical excellence and new technologies.

XenTech aim to comply with the highest quality standards. Our efforts translate into trust relationship and delivery of reliable data that meet the highest industrial standards.

cell-background

01Our team

Image

Jean-Gabriel JUDDE
PhD, President & Chief Scientific Officer

triangleDiscover linkedin
Image

Pascal LEURAUD
PhD, Chief Operating Officer

triangleDiscover
Image

Philippe MICHON
MBA, Head of Business Development

triangleDiscover linkedin
Image

Stefano CAIRO
Ph.D. Head of Molecular Biology, R&D Dept

triangleDiscover
Image

Marie CAUSSOU
Chief Financial Officer & HR Manager

triangleDiscover

Join us

triangleDiscover
Image

Laura BRULLÉ-SOUMARÉ
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover linkedin
Image

Johanna JOURDAIN
B.Sc. (Study Director, Contract Research Dept)

triangleDiscover
Image

Delphine NICOLLE
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover
Image

Marie TAVERNIER
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover linkedin
Image

Truong-An TRAN
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover

Join us

triangleDiscover
Image

Jean-Gabriel JUDDE
PhD, President & Chief Scientific Officer

triangleDiscover linkedin
Image

Pascal LEURAUD
PhD, Chief Operating Officer

triangleDiscover
Image

Philippe MICHON
MBA, Head of Business Development

triangleDiscover linkedin
Image

Stefano CAIRO
Ph.D. Head of Molecular Biology, R&D Dept

triangleDiscover
Image

Marie CAUSSOU
Chief Financial Officer & HR Manager

triangleDiscover
Image

Laura BRULLÉ-SOUMARÉ
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover linkedin
Image

Johanna JOURDAIN
B.Sc. (Study Director, Contract Research Dept)

triangleDiscover
Image

Delphine NICOLLE
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover
Image

Marie TAVERNIER
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover linkedin
Image

Truong-An TRAN
Ph.D. (Study Director, Contract Research Dept)

triangleDiscover
Image

Olivier DEAS
Ph.D. (Head of Cell Biology, R&D Dept)

triangleDiscover
Image

Laurent de SAINT RAPT
Quality Manager

triangleDiscover linkedin
Image

Josiane INGLIS
Sales Assistant

triangleDiscover

Join us

triangleDiscover
cell-background

01Our values

XenTech aim to comply with the highest quality standards. Our efforts translate into trust relationship and delivery of reliable data that meet the highest industrial standards.

PDX are not only models to study tumor progression, resistance and treatment. The use of PDX is tightly associated with a solid knowhow, high ethical standard, and strong dedication. Thanks to its quality system and the dedication of its employees, XenTech provides the highest quality data for your experiments. 

All studies are performed at a modern state-of-the-art vivarium by our committed specialists with exceptionally strong scientific and technical expertise. 

Our carefully selected and validated models are of high clinical predictivity. Thanks to the experience of our scientific team we are able to select the right model for you and offer high quality customized solutions specifically to your needs. 

During the past 15 years, we have worked with worldwide clients and performed over 2000 in vivo studies.

cell-background

01Our vision
- values

Faithfully

reproducing the biological features of human cancers in term of histology, genomics and proteomics

Providing

established concordance between patient and xenograft drug responses

Covering

molecular diversity of clinical disease

Allowing

identification of responsive cancer types

Allowing

biomarker exploratory studies for subsequent patient stratification

03Discover more

contact

Contact

triangleDiscover
talents

Talents

triangleDiscover